Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
These dynamics can rattle even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here are two mid-cap stocks with massive growth potential and one that may have trouble.
One Mid-Cap Stock to Sell:
United Therapeutics (UTHR)
Market Cap: $23.86 billion
Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ: UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.
Why Does UTHR Fall Short?
- Annual sales declines of 11.9% for the past five years show its products and services struggled to connect with the market during this cycle
- Subscale operations are evident in its revenue base of $800.5 million, meaning it has fewer distribution channels than its larger rivals
United Therapeutics is trading at $565.50 per share, or 12.3x forward price-to-sales. Dive into our free research report to see why there are better opportunities than UTHR.
Two Mid-Cap Stocks to Buy:
Nova (NVMI)
Market Cap: $16.08 billion
Headquartered in Israel, Nova (NASDAQ: NVMI) is a provider of quality control systems used in semiconductor manufacturing.
Why Should You Buy NVMI?
- Market share has increased this cycle as its 30.8% annual revenue growth over the last two years was exceptional
- Excellent operating margin of 28.8% highlights the efficiency of its business model, and it turbocharged its profits by achieving some fixed cost leverage
- Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 30.9% annually
Nova’s stock price of $508.50 implies a valuation ratio of 45.3x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Synchrony Financial (SYF)
Market Cap: $24.04 billion
Powering over 73 million active accounts and partnerships with major brands like Amazon, PayPal, and Lowe's, Synchrony Financial (NYSE: SYF) provides credit cards, installment loans, and banking products through partnerships with retailers, healthcare providers, and digital platforms.
Why Are We Bullish on SYF?
- Earnings per share have massively outperformed its peers over the last two years, increasing by 37.9% annually
- Annual tangible book value per share growth of 15.9% over the last five years was superb and indicates its capital strength increased during this cycle
- Market-beating return on equity illustrates that management has a knack for investing in profitable ventures
At $70.51 per share, Synchrony Financial trades at 7.5x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
